CHS 2017 Annual Report
The year 2017 was a remarkable one. Together, we have made noteworthy advancements
towards our vision for the inherited bleeding disorder community.
Hemophilia Today
Check out the latest issue of the CHS’ newsmagazine, Hemophilia Today, for information, current news and issues relevant to the bleeding disorder community.
Research program
The Canadian Hemophilia Society – Bayer – ADVANCE Canada Research Program was created to engage Canadian hemophilia treaters in activities to identify and research key issues in the ageing hemophilia population.
Retreat
The goal of this retreat is to address current needs of people ageing with a bleeding disorder and help address future needs. The CHS will offer about 30 sponsorships to Canadian men and women, aged 60 years and over, living with a bleeding disorder, and their caregiver/support person, to attend. The deadline to apply is September 14, 2018.
STRATEGIC PLAN | 2016‐2020
Hemlibra (emicizumab) approved by Health Canada
Please CLICK HERE to read Roche’s press release announcing the approval of Hemlibra, a new therapy for patients with hemophilia A and inhibitors.
Q&A about RFPs
We often receive questions about the tender process (RFP) for clotting factor concentrates. We produced a Q&A document which we hope will answer all your questions on the topic.
Recombinant factor concentrate charts
Please check out our updated charts listing the recombinant factor concentrates and their description.
